Literature DB >> 17223050

Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex.

Isabelle Herry1, Catherine Neukirch, Marie-Pierre Debray, Françoise Mignon, Bruno Crestani.   

Abstract

Angiomyolipomas are very common in patients with tuberous sclerosis complex (TSC) and cause substantial morbidity. Until now, arterial embolization has been the recommended treatment for symptomatic patients. We report the case of a woman with TSC and giant angiolipomas in whom sirolimus induced a dramatic reduction in bilateral renal tumors.

Entities:  

Year:  2007        PMID： 17223050     DOI： 10.1016/j.ejim.2006.07.017

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN： 0953-6205            Impact factor:   4.487


  18 in total

1.  Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration.

Authors:  J Stuart Nelson; Wangcun Jia; Thuy L Phung; Martin C Mihm
Journal:  Lasers Surg Med       Date:  2011-11-29       Impact factor: 4.025

Review 2.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:  Seth A Wander; Bryan T Hennessy; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

3.  Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86.

Authors:  Mehmet Canpolat; Huseyin Per; Hakan Gumus; Ali Yikilmaz; Ekrem Unal; Turkan Patiroglu; Levent Cinar; Ali Kurtsoy; Sefer Kumandas
Journal:  Childs Nerv Syst       Date:  2013-06-07       Impact factor: 1.475

Review 4.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

5.  Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.

Authors:  Wenbin Tan; Wangcun Jia; Victor Sun; Martin C Mihm; J Stuart Nelson
Journal:  Lasers Surg Med       Date:  2012-12-04       Impact factor: 4.025

Review 6.  The pathogenesis and imaging of the tuberous sclerosis complex.

Authors:  Henry J Baskin
Journal:  Pediatr Radiol       Date:  2008-04-15

7.  Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

Authors:  Andrew J Wagner; Izabela Malinowska-Kolodziej; Jeffrey A Morgan; Wei Qin; Christopher D M Fletcher; Natalie Vena; Azra H Ligon; Cristina R Antonescu; Nikhil H Ramaiya; George D Demetri; David J Kwiatkowski; Robert G Maki
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

8.  mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.

Authors:  David B Shackelford; Debbie S Vasquez; Jacqueline Corbeil; Shulin Wu; Mathias Leblanc; Chin-Lee Wu; David R Vera; Reuben J Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-18       Impact factor: 11.205

Review 9.  Current management of tuberous sclerosis complex.

Authors:  Darcy A Krueger; David N Franz
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 10.  Targeting the mTOR signaling network for cancer therapy.

Authors:  Funda Meric-Bernstam; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.